Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

A third of babies have peanut allergy diagnosis removed (opens in a new tab)

medicalxpress.com · 2026-11-04

Short answerEvidenceSource

Short answer

Mixed

Mixed.

3 claims go further than the study.

  • 3 supported
  • 3 overstated

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Three of six claims overstate the study. Three of six check out.

  • 3 supported
  • 3 overstated
Open claim evidence
3

The source study

An Oral Food Challenge Is Required for Accurate Diagnosis of Peanut Allergy in Infants Prior to Oral Immunotherapy: Evaluation of the Allergy Development to an Accelerated Pathway to Tolerance Peanut Oral Immunotherapy Program.

The Journal of Allergy and Clinical Immunology. in Practice · 2026
Open source record (opens in a new tab)Open in Tessa (opens in a new tab)
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

6 claims in this story

Showing all 6 claimsChoose a verdict to focus the list.

Claim 1 of 6OverstatedAlmost all babies who reacted proceeded to peanut oral immunotherapy, and 97.5% successfully started treatment at a dose guided by their challenge results.View evidenceHide evidence

As stated97.5%

Why this verdict

The 97.5% figure is supported only for the subgroup of 394 infants who commenced OIT. The claim that almost all babies who reacted proceeded to OIT is not supported by the abstract profile; 507 infants had positive TOFCs, while only 394 are described as commencing OIT, and selection/reasons for non-commencement are not detailed.

1

Study evidence

Among infants who commenced peanut OIT within ADAPT (n=394), 97.5% (384 of 394) successfully initiated treatment at a starting dose below the TOFC-determined eliciting threshold.97.5% (384/394)

“Among 394 infants commencing OIT, 97.5% (384 of 394) successfully initiated treatment at a dose below the TOFC-determined threshold.”
2

Study evidence

TOFC positivity rate among infants undergoing challenge65.2% positive (507 of 778); 34.8% negative (271 of 778)

“We evaluated the diagnostic accuracy and safety of this approach before starting OIT across the 10 ADAPT public hospital sites.”
Claim 2 of 6OverstatedThe article says the findings come from an evaluation of the ADAPT Peanut Oral Immunotherapy Program, involving 1,275 infants under 18 months old, with 778 undergoing oral food challenge across multiple Australian states.View evidenceHide evidence

As stated1,275 infants; 778 challenged

Why this verdict

The numbers 1,275 assessed and 778 undergoing TOFC are supported, and the program involved 10 public hospital sites. However, the supplied paper profile describes eligibility as infants under 12 months at entry, with median TOFC age 13 months; it does not support the story's 'under 18 months' framing or verify 'multiple Australian states' at abstract depth.

1

Study evidence

TOFC positivity rate among infants undergoing challenge65.2% positive (507 of 778); 34.8% negative (271 of 778)

“We evaluated the diagnostic accuracy and safety of this approach before starting OIT across the 10 ADAPT public hospital sites.”
Claim 3 of 6OverstatedThe article says clinical history and allergy testing alone were not enough to accurately diagnose peanut allergy in many cases, and that supervised oral food challenge should be routinely considered before an infant starts oral immunotherapy.View evidenceHide evidence

Why this verdict

The abstract profile supports an associational diagnostic-yield interpretation: many infants with prior reaction and sensitization had negative TOFCs, and sensitization measures did not predict threshold or severity. But the story frames this as a strong, unhedged practice conclusion that history and testing were not enough and OFC should routinely be considered before OIT; given the retrospective, selected observational cohort, this is stronger than the evidence alone warrants, even though it aligns with the authors' conclusion.

1

Study evidence

TOFC positivity rate among infants undergoing challenge65.2% positive (507 of 778); 34.8% negative (271 of 778)

“We evaluated the diagnostic accuracy and safety of this approach before starting OIT across the 10 ADAPT public hospital sites.”
2

Study evidence

Median skin prick test (SPT) and Ara h 2 specific IgE values were higher in infants with positive TOFCs than in those with negative TOFCs.

“Median skin prick test and Ara h 2 specific IgE results were higher in positive versus negative TOFCs but did not predict the reaction threshold or severity.”
Claim 4 of 6SupportedA third of babies thought to have a peanut allergy could safely have the diagnosis removed after supervised oral food challenge.View evidenceHide evidence

As stateda third / 35%

Why this verdict

The abstract-profile evidence reports 34.8% negative TOFCs among infants with prior reaction and sensitization, enabling delabeling. The headline wording is less precise than the body because it says broadly 'babies thought to have a peanut allergy,' but the magnitude and supervised-delabeling point are supported for the studied ADAPT cohort.

1

Study evidence

TOFC positivity rate among infants undergoing challenge65.2% positive (507 of 778); 34.8% negative (271 of 778)

“We evaluated the diagnostic accuracy and safety of this approach before starting OIT across the 10 ADAPT public hospital sites.”
Claim 5 of 6SupportedThe study found that 35% of infants with a recent reaction to peanut and a positive allergy test did not react during an oral food challenge.View evidenceHide evidence

As stated35%

Why this verdict

The profile reports 778 infants underwent TOFC and 34.8% (271/778) were negative, i.e. did not react, in a cohort defined by prior reaction and sensitization.

1

Study evidence

TOFC positivity rate among infants undergoing challenge65.2% positive (507 of 778); 34.8% negative (271 of 778)

“We evaluated the diagnostic accuracy and safety of this approach before starting OIT across the 10 ADAPT public hospital sites.”
Claim 6 of 6SupportedThe study found that while 65% of babies reacted during challenge, including 12% who experienced anaphylaxis, all episodes were safely managed.View evidenceHide evidence

As stated65%; 12%

Why this verdict

The profile reports TOFCs were positive in 65.2% (507/778), anaphylaxis occurred in 12.0% of positive OFCs, and events were reported as safely managed in the program.

1

Study evidence

TOFC positivity rate among infants undergoing challenge65.2% positive (507 of 778); 34.8% negative (271 of 778)

“We evaluated the diagnostic accuracy and safety of this approach before starting OIT across the 10 ADAPT public hospital sites.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The paper profile identifies the design as a retrospective multicenter chart review/quality-assurance evaluation.

    The story describes a program evaluation but the supplied caveats do not indicate that the evidence came from retrospective chart review, an important limitation for ascertainment and causal/practice-strength interpretation.

    From Retrospective multicenter chart review; retrospective chart review; Retrospective chart review (program implementation s

  • The OIT initiation result applies only to infants commencing OIT: 97.5% of 394 successfully initiated below the TOFC-determined threshold.

    The story reports the 97.5% figure but does not preserve the important subset caveat and instead says almost all babies who reacted proceeded to OIT.

    From Retrospective chart review (program implementation subset)

  • The abstract profile provides limited detail on severity grading, event adjudication, dose-distribution, OIT selection criteria, and longer-term OIT outcomes.

    The story's listed caveats do not mention these abstract-level reporting limitations, which affect interpretation of safety and implementation claims.

    From Retrospective multicenter chart review; Retrospective chart review (program implementation subset)

4 things the story did carry across
  • The central result was that 34.8% of TOFCs were negative and 65.2% were positive among 778 infants undergoing challenge.
  • The study population was a selected ADAPT cohort with prior grade 1–2 peanut reaction and sensitization, not a general population of all infants suspected of peanut allergy.
  • TOFCs had a measurable anaphylaxis risk: 12.0% of positive OFCs, 7.8% overall, with events reported as safely managed.
  • Baseline skin prick test and Ara h 2 specific IgE were higher in positive TOFCs but did not predict reaction threshold or severity.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

3

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoEvaluate, across the 10-site ADAPT program, the diagnostic accuracy and safety of performing threshold oral food challenges (TOFCs) in infants before starting peanut oral immunotherapy (OIT), including the extent of negative challenges (delabeling) and adverse events such as anaphylaxis.Retrospective multicenter chart reviewExpand

In plain English

Retrospective, multicenter (10 public hospital sites) evaluation of threshold oral food challenges (TOFCs) performed before peanut oral immunotherapy (OIT) in infants meeting eligibility (prior grade 1–2 reaction and peanut sensitization). The study reports TOFC positivity/negativity (diagnostic yield/delabeling), eliciting doses, and safety outcomes including anaphylaxis, and describes subsequent OIT initiation relative to TOFC-determined thresholds.

Key findings

  • TOFC positivity rate among infants undergoing challenge65.2% positive (507 of 778); 34.8% negative (271 of 778)
  • Eliciting dose among positive TOFCsMedian eliciting dose 120 mg peanut protein
“We evaluated the diagnostic accuracy and safety of this approach before starting OIT across the 10 ADAPT public hospital sites.”
What this piece can’t prove
  • Study population restricted to infants meeting ADAPT enrollment criteria (prior grade 1–2 reaction and sensitization), which may limit generalizability.
  • Abstract provides limited detail on TOFC dose-distribution, severity grading criteria beyond reported anaphylaxis counts, and on event adjudication methods.

1 further detail could not be confirmed from the summary.

2human in vivoAssess whether baseline sensitization measures (skin prick test and peanut/Ara h 2 specific IgE) predict TOFC outcomes (positive vs negative) and clinical characteristics of reactions (eliciting dose/threshold and severity).retrospective chart reviewExpand

In plain English

In infants assessed in the ADAPT program who underwent threshold oral food challenge (TOFC), baseline sensitization measures (skin prick test [SPT] and peanut/Ara h 2 specific IgE) were higher in infants with positive TOFCs than in those with negative TOFCs, but these measures did not predict the reaction eliciting dose (threshold) or severity.

Key findings

  • Median skin prick test (SPT) and Ara h 2 specific IgE values were higher in infants with positive TOFCs than in those with negative TOFCs.
  • Baseline SPT and Ara h 2 specific IgE did not predict the reaction eliciting dose (threshold) or the severity of reactions during TOFC.
“Median skin prick test and Ara h 2 specific IgE results were higher in positive versus negative TOFCs but did not predict the reaction threshold or severity.”
What this piece can’t prove
  • Retrospective chart review design (risk of incomplete or inconsistent documentation).
  • Study population limited to infants meeting prespecified sensitization and clinical-eligibility criteria (SPT ≥ 3 mm or sIgE ≥ 0.35 kUA/L and prior grade 1–2 reaction), which may restrict applicability to broader infant populations.

1 further detail could not be confirmed from the summary.

3human in vivoEvaluate whether TOFC-derived eliciting thresholds can be used operationally to select safe starting OIT doses (i.e., successful initiation below the TOFC-determined threshold) among infants commencing OIT.Retrospective chart review (program implementation subset)Expand

In plain English

In a retrospective chart-review subset of the ADAPT program, 394 infants who commenced peanut OIT were assessed for whether their OIT starting dose was below the threshold eliciting dose determined by a prior threshold oral food challenge (TOFC); 97.5% (384/394) successfully initiated OIT at a dose below the TOFC-determined threshold.

Key findings

  • Among infants who commenced peanut OIT within ADAPT (n=394), 97.5% (384 of 394) successfully initiated treatment at a starting dose below the TOFC-determined eliciting threshold.97.5% (384/394)
“Among 394 infants commencing OIT, 97.5% (384 of 394) successfully initiated treatment at a dose below the TOFC-determined threshold.”
What this piece can’t prove
  • Subset analysis of program participants who commenced OIT (n=394); not a randomized comparison.
  • Abstract lacks detail on selection criteria for commencing OIT, procedures and monitoring during initiation, and safety/adverse event rates specific to OIT initiation.
  • Retrospective chart-review data source may limit completeness and uniformity of outcome ascertainment.
Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Open the paper in Tessa

An Oral Food Challenge Is Required for Accurate Diagnosis of Peanut Allergy in Infants Prior to Oral Immunotherapy: Evaluation of the Allergy Development to an Accelerated Pathway to Tolerance Peanut Oral Immunotherapy Program.

The journal of allergy and clinical immunology. In practice · 2026

Deep dive in Tessa (opens in a new tab)Source record (opens in a new tab)

Why this one

Near certain

NewsLink found the paper. Tessa is where you inspect it deeply.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 15 candidate papers

Selected

An Oral Food Challenge Is Required for Accurate Diagnosis of Peanut Allergy in Infants Prior to Oral Immunotherapy: Evaluation of the Allergy Development to an Accelerated Pathway to Tolerance Peanut Oral Immunotherapy Program.

The Journal of Allergy and Clinical Immunology. in Practice · 2026 · PubMed, Europe PMC, Crossref

Tessa (opens in a new tab)Source (opens in a new tab)
Candidate

Markers associated with adverse reactions during peanut oral food challenge after peanut oral immunotherapy

Journal of Allergy and Clinical Immunology · 2024 · Crossref

Source (opens in a new tab)
Candidate

Developing a Standardised National Model of Care for Treatment of Peanut Allergy in Infants: The ADAPT Peanut Oral Immunotherapy Program.

Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology · 2026 · PubMed

Tessa (opens in a new tab)Source (opens in a new tab)

And 9 more candidates considered.